File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant

TitleInduction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant
Authors
KeywordsASP-1
H5N1
M2e
Vaccine
Issue Date2010
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2010, v. 28 n. 44, p. 7233-7240 How to Cite?
Abstract
Our previous studies have shown the adjuvanticity of an Onchocerca volvulus recombinant protein, Ov-ASP-1 (ASP-1), when administered in an aqueous formulation with bystander vaccine antigens or commercial vaccines. In this study, we reported a novel formulation that took advantage of the protein nature of the ASP-1 adjuvant by creating recombinant fusion protein vaccines linking the highly conserved extracellular domain of M2 protein (M2e) consensus sequence of H5N1 influenza viruses with the ASP-1 adjuvant. Two recombinant fusion proteins designated M2e-ASP-1 and M2e3-ASP-1 were studied, in which ASP-1 was fused with one or three tandem copies of the M2e antigen. Our results show that these novel recombinant influenza vaccines, particularly M2e3-ASP-1, induced strong anti-M2e-specific humoral and cellular immune responses in the established mouse model. Furthermore, M2e3-ASP-1 was able to provide significant cross-clade protection against divergent H5N1 viruses. Consequently, this study has demonstrated a potential novel vaccine formulation that could provide a complementary prophylactic strategy in preventing the threat of future influenza outbreak resulting from rapid evolution of the H5N1 virus and co-circulation of multiple antigenic variants in various regions. © 2010 Elsevier Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/135278
ISSN
2013 Impact Factor: 3.485
ISI Accession Number ID
Funding AgencyGrant Number
National 863 Program of China2006AA02Z406
National 973 Program of China2005CB523001
NSFC30901371
Mega-projects of Science Research2009ZX10004-401
University Grants CommitteeAoE/M-12/06
Research Fund for the Control of Infectious Diseases, Hong Kong SAR09080812
Funding Information:

This study was supported by National 863 Program of China (2006AA02Z406), National 973 Program of China (2005CB523001), NSFC (30901371), Mega-projects of Science Research for the 11th Five-Year Plan (2009ZX10004-401), the Area of Excellence Scheme of the University Grants Committee (Grant AoE/M-12/06) and Research Fund for the Control of Infectious Diseases (09080812), Hong Kong SAR.

References
Grants

 

Author Affiliations
  1. Institute of Microbiology Chinese Academy of Sciences
  2. The University of Hong Kong
  3. New York Blood Center
DC FieldValueLanguage
dc.contributor.authorZhao, Gen_HK
dc.contributor.authorDu, Len_HK
dc.contributor.authorXiao, Wen_HK
dc.contributor.authorSun, Sen_HK
dc.contributor.authorLin, Yen_HK
dc.contributor.authorChen, Men_HK
dc.contributor.authorKou, Zen_HK
dc.contributor.authorHe, Yen_HK
dc.contributor.authorLustigman, Sen_HK
dc.contributor.authorJiang, Sen_HK
dc.contributor.authorZheng, BJen_HK
dc.contributor.authorZhou, Yen_HK
dc.date.accessioned2011-07-27T01:31:07Z-
dc.date.available2011-07-27T01:31:07Z-
dc.date.issued2010en_HK
dc.identifier.citationVaccine, 2010, v. 28 n. 44, p. 7233-7240en_HK
dc.identifier.issn0264-410Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/135278-
dc.description.abstractOur previous studies have shown the adjuvanticity of an Onchocerca volvulus recombinant protein, Ov-ASP-1 (ASP-1), when administered in an aqueous formulation with bystander vaccine antigens or commercial vaccines. In this study, we reported a novel formulation that took advantage of the protein nature of the ASP-1 adjuvant by creating recombinant fusion protein vaccines linking the highly conserved extracellular domain of M2 protein (M2e) consensus sequence of H5N1 influenza viruses with the ASP-1 adjuvant. Two recombinant fusion proteins designated M2e-ASP-1 and M2e3-ASP-1 were studied, in which ASP-1 was fused with one or three tandem copies of the M2e antigen. Our results show that these novel recombinant influenza vaccines, particularly M2e3-ASP-1, induced strong anti-M2e-specific humoral and cellular immune responses in the established mouse model. Furthermore, M2e3-ASP-1 was able to provide significant cross-clade protection against divergent H5N1 viruses. Consequently, this study has demonstrated a potential novel vaccine formulation that could provide a complementary prophylactic strategy in preventing the threat of future influenza outbreak resulting from rapid evolution of the H5N1 virus and co-circulation of multiple antigenic variants in various regions. © 2010 Elsevier Ltd.en_HK
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_HK
dc.relation.ispartofVaccineen_HK
dc.subjectASP-1en_HK
dc.subjectH5N1en_HK
dc.subjectM2een_HK
dc.subjectVaccineen_HK
dc.subject.meshAdjuvants, Immunologic - administration and dosage - pharmacology-
dc.subject.meshAntigens, Helminth - administration and dosage - immunology-
dc.subject.meshHelminth Proteins - administration and dosage - immunology-
dc.subject.meshInfluenza A Virus, H5N1 Subtype - immunology-
dc.subject.meshInfluenza Vaccines - immunology-
dc.titleInduction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvanten_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0264-410X&volume=28&issue=44&spage=7233&epage=7240&date=2010&atitle=Induction+of+protection+against+divergent+H5N1+influenza+viruses+using+a+recombinant+fusion+protein+linking+influenza+M2e+to+Onchocerca+volvulus+activation+associated+protein-1+(ASP-1)+adjuvant-
dc.identifier.emailZheng, BJ:bzheng@hkucc.hku.hken_HK
dc.identifier.authorityZheng, BJ=rp00353en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.vaccine.2010.08.049en_HK
dc.identifier.pmid20732469en_HK
dc.identifier.scopuseid_2-s2.0-77957821697en_HK
dc.identifier.hkuros188636en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77957821697&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume28en_HK
dc.identifier.issue44en_HK
dc.identifier.spage7233en_HK
dc.identifier.epage7240en_HK
dc.identifier.isiWOS:000283980400015-
dc.publisher.placeUnited Kingdomen_HK
dc.relation.projectControl of Pandemic and Inter-pandemic Influenza-
dc.relation.projectCross-protective efficacy of immunization with different forms of M2 vaccines and their combinations with HA vaccines against highly pathogenic H5N1 influenza A viruses in mice-
dc.identifier.scopusauthoridZhao, G=8684553000en_HK
dc.identifier.scopusauthoridDu, L=8686996200en_HK
dc.identifier.scopusauthoridXiao, W=9245533300en_HK
dc.identifier.scopusauthoridSun, S=35171536200en_HK
dc.identifier.scopusauthoridLin, Y=23479885500en_HK
dc.identifier.scopusauthoridChen, M=35168778400en_HK
dc.identifier.scopusauthoridKou, Z=23034818200en_HK
dc.identifier.scopusauthoridHe, Y=8742157400en_HK
dc.identifier.scopusauthoridLustigman, S=7003666182en_HK
dc.identifier.scopusauthoridJiang, S=7404453146en_HK
dc.identifier.scopusauthoridZheng, BJ=7201780588en_HK
dc.identifier.scopusauthoridZhou, Y=8791655300en_HK
dc.identifier.citeulike7716681-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats